Business Context and Reporting Period
Company: Gladstone Investment Corporation (GAIN)
Filing Type: Form 8-K (Current Report)
Date of Report: August 7, 2023
Principal Activity: Entry into a Material Definitive Agreement regarding the issuance of common stock.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a disclosure of a capital raising mechanism rather than a financial performance report.
- Proposed Issuance: Up to $50 million of common stock.
- Commission Rate: Up to 2.0% of the gross sales price per share sold.
- Securities Registered: Common Stock (GAIN), 5.00% Notes due 2026 (GAINN), 4.875% Notes due 2028 (GAINZ), and 8.00% Notes due 2028 (GAINL).
Material Changes
On August 7, 2023, the Company executed the following material changes to its capital raising structure:
- New Sales Agreement: Entered into an agreement with B. Riley Securities, Inc. to act as a sales agent for the issuance of up to $50 million of common stock.
- Amendments to Existing Agreements: Amended existing sales agreements with Oppenheimer & Co. Inc. and Virtu Americas LLC to include B. Riley as an "Other Agent."
- Agent Structure: The Company now utilizes three sales agents (Oppenheimer, Virtu, and B. Riley) under a unified framework.
Guidance, Outlook, and Risks
Management Commentary: The Company has established an "at-the-market" offering program where the sales agents are not required to sell any specific number or dollar amount of securities. Sales will be made using commercially reasonable efforts consistent with normal trading practices.
Risks and Contingencies:
- Underwriter Status: B. Riley is deemed an "underwriter" under the Securities Act of 1933.
- Indemnification: The Company has agreed to indemnify and contribute to B. Riley against certain civil liabilities.
- Legal Opinion: Kirkland & Ellis LLP provided a legality opinion regarding the shares to be sold.
Investor Verification Checklist
- Verify the current market price of GAIN common stock to assess potential dilution from the $50 million issuance.
- Review the full text of the Sales Agreement (Exhibit 1.1) and Amendments (Exhibits 1.2 and 1.3) for specific termination rights and pricing mechanisms.
- Monitor future filings to determine the actual volume of shares sold and the total commissions paid to the sales agents.
- Confirm the status of the Company's existing debt obligations (Notes due 2026, 2028) in subsequent periodic reports.